EUVIMEDEUVIMED entdecken
Open Access

Peripheral CCL2-CCR2 signalling contributes to chronic headache-related sensitization

Sun Ryu, Xuemei Liu, Tingting Guo, Zhaohua Guo, Jintao Zhang, Yu-Qing Cao iD

Brain · 03.10.2023 · 146 (10) · 4274-4291

DOI: 10.1093/brain/awad191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 07.06.2023. Verfasst von Sun Ryu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Washington University Pain Center, Washington University School of Medicine, Campus Box MSC 8054-86-05, St. Louis, M…. Hauptthemen laut MEDLINE: Chemokine CCL2, Migraine Disorders, Receptors, CCR2. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Department of Defense award, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Migraine, especially chronic migraine, is highly debilitating and still lacks effective treatment. The persistent headache arises from activation and sensitization of primary afferent neurons in the trigeminovascular pathway, but the underlying mechanisms remain incompletely understood. Animal studies indicate that signalling through chemokine C-C motif ligand 2 (CCL2) and C-C motif chemokine receptor 2 (CCR2) mediates the development of chronic pain after tissue or nerve injury. Some migraine patients had elevated CCL2 levels in CSF or cranial periosteum. However, whether the CCL2-CCR2 signalling pathway contributes to chronic migraine is not clear. Here, we modelled chronic headache with repeated administration of nitroglycerin (NTG, a reliable migraine trigger in migraineurs) and found that both Ccl2 and Ccr2 mRNA were upregulated in dura and trigeminal ganglion (TG) tissues that are implicated in migraine pathophysiology. In Ccl2 and Ccr2 global knockout mice, repeated NTG administration did not evoke acute or persistent facial skin hypersensitivity as in wild-type mice. Intraperitoneal injection of CCL2 neutralizing antibodies inhibited chronic headache-related behaviours induced by repeated NTG administration and repetitive restraint stress, suggesting that the peripheral CCL2-CCR2 signalling mediates headache chronification. We found that CCL2 was mainly expressed in TG neurons and cells associated with dura blood vessels, whereas CCR2 was expressed in subsets of macrophages and T cells in TG and dura but not in TG neurons under both control and disease states. Deletion of Ccr2 gene in primary afferent neurons did not alter NTG-induced sensitization, but eliminating CCR2 expression in either T cells or myeloid cells abolished NTG-induced behaviours, indicating that both CCL2-CCR2 signalling in T cells and macrophages are required to establish chronic headache-related sensitization. At cellular level, repeated NTG administration increased the number of TG neurons that responded to calcitonin-gene-related peptide (CGRP) and pituitary adenylate cyclase activating polypeptide (PACAP) as well as the production of CGRP in wild-type but not Ccr2 global knockout mice. Lastly, co-administration of CCL2 and CGRP neutralizing antibodies was more effective in reversing NTG-induced behaviours than individual antibodies. Taken together, these results suggest that migraine triggers activate CCL2-CCR2 signalling in macrophages and T cells. This consequently enhances both CGRP and PACAP signalling in TG neurons, ultimately leading to persistent neuronal sensitization underlying chronic headache. Our work not only identifies the peripheral CCL2 and CCR2 as potential targets for chronic migraine therapy, but also provides proof-of-concept that inhibition of both peripheral CGRP and CCL2-CCR2 signalling is more effective than targeting either pathway alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CCL2Migraine DisordersReceptors, CCR2AnimalsMiceCalcitonin Gene-Related PeptideHeadacheMice, KnockoutPituitary Adenylate Cyclase-Activating PolypeptideReceptors, Chemokine

Stichwörter der Autor:innen

CCL2CCR2headachemigraineneuroimmune interactionperipheral sensitization

Substanzen

Calcitonin Gene-Related PeptideCCL2 protein, humanCCR2 protein, humanChemokine CCL2Pituitary Adenylate Cyclase-Activating PolypeptideReceptors, CCR2Receptors, Chemokine

Autor:innen und Institutionen

  • Department of Anesthesiology and Washington University Pain Center, Washington University School of Medicine, Campus Box MSC 8054-86-05, St. Louis, MO 63110, USA.

ORCID-Profile: Yu-Qing Cao

Förderung

  • NINDS NIH HHS
  • Department of Defense award
  • National Institute of Health

Zitieren

APA

Ryu, S., Liu, X., Guo, T., Guo, Z., Zhang, J., & Cao, Y. Q. (2023). Peripheral CCL2-CCR2 signalling contributes to chronic headache-related sensitization. Brain, 146(10), 4274-4291. https://doi.org/10.1093/brain/awad191

Vancouver

Ryu S, Liu X, Guo T, Guo Z, Zhang J, Cao YQ. Peripheral CCL2-CCR2 signalling contributes to chronic headache-related sensitization. Brain. 2023;146(10):4274-4291. doi:10.1093/brain/awad191

BibTeX
@article{Ryu2023,
  author = {Ryu, Sun and Liu, Xuemei and Guo, Tingting and Guo, Zhaohua and Zhang, Jintao and Cao, Yu-Qing},
  title = {Peripheral CCL2-CCR2 signalling contributes to chronic headache-related sensitization},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {10},
  pages = {4274--4291},
  doi = {10.1093/brain/awad191}
}
Kostenlos starten →